U.S. Markets closed
  • S&P 500

    4,246.59
    -8.56 (-0.20%)
     
  • Dow 30

    34,299.33
    -94.42 (-0.27%)
     
  • Nasdaq

    14,072.86
    -101.29 (-0.71%)
     
  • Russell 2000

    2,320.07
    -6.07 (-0.26%)
     
  • Crude Oil

    72.46
    +0.34 (+0.47%)
     
  • Gold

    1,859.10
    +2.70 (+0.15%)
     
  • Silver

    27.80
    +0.11 (+0.39%)
     
  • EUR/USD

    1.2133
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    1.4990
    -0.0020 (-0.13%)
     
  • Vix

    17.02
    +0.63 (+3.84%)
     
  • GBP/USD

    1.4078
    -0.0005 (-0.0324%)
     
  • USD/JPY

    110.0800
    +0.0460 (+0.0418%)
     
  • BTC-USD

    40,239.19
    -255.43 (-0.63%)
     
  • CMC Crypto 200

    995.03
    -15.57 (-1.54%)
     
  • FTSE 100

    7,172.48
    +25.80 (+0.36%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

Seelos Therapeutics to Participate in Investor Conferences in November

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Oct. 22, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in two investor conferences in November.

(PRNewsfoto/Seelos Therapeutics, Inc.)
(PRNewsfoto/Seelos Therapeutics, Inc.)

Seelos Therapeutics' senior management will participate in:

  • Jefferies Virtual Global Healthcare Conference, Tuesday-Thursday, November 17-19

  • Benchmark Virtual Discovery One on One Investor Conference, Wednesday, November 18

Raj Mehra, Ph.D., Chairman and CEO and Dr. Tim Whitaker, MD, Head of Research and Development, will host 1x1 meetings via conference calls.

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-investor-conferences-in-november-301157408.html

SOURCE Seelos Therapeutics, Inc.